BA9™ designed specifically for coronary stent application

Bridging science and innovative technology

In the early 2000's the available mTOR inhibitor limus drugs, available for coronary stenting, were developed for systemic application. Biosensors developed its own
proprietary limus technology by focusing during the early stages of drug development on its use for vascular technologies

BA9™ Designed for Vascular Stent Technologies, optimized for local drug delivery

The Research and Development team developed several versions of Biolimus, through a number of iterations ultimately decided to focus on BA9™ (Biolimus A9™), as the best
option for coronary stent application. Consequently, Biosensors' proprietary limus drug BA9™ was used within its BioMatrix™ DES family and BioFreedom™ DCS.

BA9™ key characteristics. 10 times more lipophilic than Sirolimus1

> Slower metabolism of drug due to its structure
> High local bioavailability2
> Long 20-day in tissue half-life2

12244-000-EN, 11521-000-EN, 11463-000-EN - Rev.01 + 11881-000-EN - Rev.04
1. Data on file Biosensors International Group, Ltd. - Report RD - 00020 - Validation/Verification of ElogPoct Determination Method and Measurement of ElogPoct for Zotarolimus
2. Polymer-Free Biolimus A9–Coated Stent Demonstrates More Sustained Intimal Inhibition, Improved Healing, and Reduced Inflammation Compared With a Polymer-Coated Sirolimus-Eluting
Cypher Stent in a Porcine Model. Tada N Circ Cardiovasc Interv. 2010;3:174-183


CAUTION: Please note that the following pages are exclusively reserved for Health Care Professionals in countries with applicable health authority product registrations. To the extent this site contains information intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions. Please contact your Biosensors International representative for availability or the products and registration status.

The law restricts these devices to sale by or on the order of a physician. Prior to use, it is important to read the "Instructions for Use" supplied with these devices for indications, contraindications, suggested procedures, warnings, and precautions.

Biosensors’ interventional cardiology products, including BioMatrix NeoFlex™, BioMatrix™ Alpha, BioFreedom™, BioFreedom™ Ultra, Chroma™, BioStream™, BMX-J®, BioPath™, Powerline™, RISE™ NC, are not available for sale in the United States and certain other countries. ALLEGRA™ is a product of NVT AG. Blue Sail Medical Co., Ltd is the parent company of NVT AG and Biosensors International Group, Ltd. and its affliates are collaborating for the commercialization of the ALLEGRA™ device.

BioMatrix NeoFlex, BioMatrix Alpha, BioFreedom, BioFreedom Ultra, Chroma, BioStream, BMX-J, BioPath, Juno, S-Stent, Powerline, Rise NC and Quadrature Link are trademarks or registered trademarks of Biosensors International Group, Ltd. ALLEGRA is a trademark or registered trademark of NVT AG. ALLEGRA™ is CE Mark approved (CE 0124). All other cited trademarks are the property of their respective owners.